OLGA and OLGIM Stage System for Gastric Cancer

The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03380052

Enrollment

2900

Registered

2017-12-20

Start date

2006-02-28

Completion date

2022-01-31

Last updated

2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Gastritis, Intestinal Metaplasia, Stomach Neoplasms

Keywords

OLGA, OLGIM, Helicobacter pylori, Gastric cancer, pepsinogen

Brief summary

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

Detailed description

To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is high. In addition, the investigators attempted to investigate the interaction among the several risk factors including OLGA or OLGIM staging system for the risk of GC to help establish surveillance strategy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Control group * those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy * Gastric cancer group * Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.

Exclusion criteria

* history of previous gastrointestinal surgery, * any other malignancy * cardia cancer * who do not perform endoscopic biopsy * pathologically proven gastric dysplasia

Design outcomes

Primary

Measure	Time frame	Description
The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk	per 1 year	To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification

Countries

South Korea

Outcome results